

LONG TERM AND CLINICAL EFFECTS OF AN PHARMACOVIGILANCE EDUCATIONAL INTERVENTION IN SPECIALIST ONCOLOGY NURSES

M.Reumerman^{1,2}, J. Tichelaar^{1,2}, R.van. Eekeren³, M.C. Richir^{1,2}, M.A. van Agtmael^{1,2}

1 Department of Internal Medicine, Section Pharmacotherapy, VU University Medical Center, Amsterdam, the Netherlands 2 RECIPE (Research & Expertise Center In Pharmacotherapy Education), Amsterdam, the Netherlands 3 The Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.

Background

- (Specialized) nurses can play an important role in monitoring adverse drug reaction (ADR).




160 ADR-reports by nurses each year.

- Previous studies have shown an increase in competences after an educational intervention.
- Long-term and clinical effects remain unknown.

Aim

Investigate the clinical and long-term effects of a pharmacovigilance educational intervention in specialist oncology nurses (SONs).

Methods



Intervention group:

SONs in a prescribing qualification course WITH pharmacovigilance education.

Control group:

SONs in a prescribing qualification course WITHOUT pharmacovigilance education.

Outcome measures



of ADRs during intervention # ADRs after intervention



T0-survey (direct after qualification)
T1-survey (one year after qualification)
On attitude and knowledge

Our pharmacovigilance educational intervention shows:

- Significant and relevant increase in reported ADRs after a single educational intervention.
- Immediate and sustainable long-term increase in pharmacovigilance competences.

Results


<u>Inclusion</u>



60x SONs in intervention group

10x SONs in control group

Clinical results



70x total
10x after intervention
0x total

Attitudinal results



Physician

3,5 / 5,0



Pharmacist

3,4 / 5,0 3,5 / 5,0




SON


3,7 / 5,0 1,8 / 5,0

SONs opinion on most relevant healthcare professionals in pharmacovigilance

Knowledge results

[5-point likert scale].





SONs mean pharmacovigilance knowledge score at T0 and T1.



netherlands pharmacovigilance centrelareb

Contact: M. Reumerman m.reumerman@vumc.nl
No conflicts of interests to declare.